Epizyme Appoints Oncology Industry Leader Michael Giordano, MD, to its Board of Directors - NASDAQ Stock Market -BoardProspects

Epizyme Appoints Oncology Industry Leader Michael Giordano, MD, to its Board of Directors

NASDAQ Stock Market Mar 12 2018 BoardMoves

CAMBRIDGE, Mass., March 12, 2018 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced the appointment of Michael Giordano, M.D., to the company's board of directors . Dr. Giordano brings to the ...
Read Full Article

Bookmark or Share this article

Login to comment.
Related Articles
- PepsiCo Puts Trian Business Advisor On Board also categorized in BoardMoves
- Pfizer Spinoff Zoetis Takes Pershing Square's Doyle Onto Board also categorized in BoardMoves
- Yahoo co-founder David Filo nominated for company's new board member also categorized in BoardMoves
- Pandora Jewelry Names New CEO and Board Chairman also categorized in BoardMoves
- What Lies Ahead For Chesapeake As McClendon Exits? also categorized in BoardMoves
- Target CEO Gregg Steinhafel Resigns In Data Breach Fallout also categorized in BoardMoves
- Lombard Medical Names David Milne to Board of Directors also published in NASDAQ Stock Market
- OraSure Technologies Appoints Mara G. Aspinall to Board of Directors also published in NASDAQ Stock Market
- Airbnb Adds Outgoing American Express CEO Kenneth Chenault To Board of Directors also categorized in BoardMoves
- Twitter's Jack Dorsey To Join Disney Board Of Directors also categorized in BoardMoves

Search:
Categories
1. BoardProspects Features:
  BoardBlogs, BoardKnowledge, BoardMoves, BoardNews, BoardProspects Announcements, BoardProspects CEO, CEO Blog, In the News, Partner Publications, Sponsored Content
Quotes
1. Michael is a highly respected oncology leader, bringing us a wealth of experience developing novel and highly successful cancer therapies.
2. In working alongside the Epizyme team, I have been impressed by their passion and commitment to bringing new medicines to patients in need.
Topics Mentioned